Merck's efinopegdutide drug yields positive results in MASH trial
📊 MRK — Piyasa Yorumu
▲ up · 62%Merck's efinopegdutide yielding positive results in its MASH trial is a moderately positive catalyst, particularly signaling growth potential in the metabolic diseases area. The price is trading just above the SMA20 and SMA50 at the last close of 148.44; RSI is around 55, far from overbought territory, and MACD is near zero, meaning momentum is not yet strong. The news could trigger an upward reaction in the short term, but MACD remaining below the signal line and weak momentum suggest the move may be limited. I expect a moderately positive trend in the 1-3 day outlook; volume and details of the news (phase, effect size) will determine the direction. For a definitive uptrend, MACD needs to cross above the signal line and volume confirmation is required.